Physician profile
Suzanne Wallis
NPI 1346603925
$2,343.06
in general payments reported to CMS, 2019-2025
28 companies · $688 in 2025
The $688 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $245 · 2022: $328 · 2023: $547 · 2024: $534 · 2025: $688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,769.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $421.81 | 2022-2025 | Nuzyra |
| Vanda Pharmaceuticals INC. | $354.31 | 2023-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $317.94 | 2022-2025 | |
| Corium, LLC | $154.13 | 2022-2024 | Azstarys |
| Pfizer INC. | $131.84 | 2022-2023 | |
| Lilly USA, LLC | $106.53 | 2023-2025 | Mounjaro |
| Sanofi Pasteur INC. | $96.78 | 2021-2025 | |
| Tris Pharma INC | $80.49 | 2021-2022 | |
| Axsome Therapeutics, INC. | $75.70 | 2023-2025 | Auvelity |
| Phadia US INC. | $63.76 | 2021-2023 | Immunocap |
| Takeda Pharmaceuticals U.S.A., INC. | $62.77 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $59.85 | 2021-2025 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $48.57 | 2024 | Gardasil, Gardasil 9, M-M-R II |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.59 | 2022-2025 | Caplyta |
| Novo Nordisk INC | $42.85 | 2024 | Ozempic, Rybelsus |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $30.85 | 2021 | |
| Abbott Laboratories | $30.40 | 2021 | |
| Ironshore Pharmaceuticals INC. | $30.10 | 2021-2022 | |
| Ucb, INC. | $28.73 | 2024 | Briviact |
| Qiagen, LLC | $25.89 | 2023 | |
| Indivior INC. | $23.06 | 2023 | Sublocade |
| Ars Pharmaceuticals Operations, INC. | $21.44 | 2025 | Neffy |
| Biohaven Pharmaceutical Holding Company LTD. | $20.78 | 2022 | |
| Adlon Therapeutics L.P. | $17.76 | 2021 | |
| Lundbeck LLC | $17.66 | 2024 | Rexulti |
| Glaxosmithkline, LLC. | $16.27 | 2025 | Penmenvy, Bexsero |
| Collegium Pharmaceutical, INC. | $13.54 | 2025 | Jornay Pm |
| Genentech USA, INC. | $4.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Wallis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.